50P HER2/HER3 heterodimerization can define ER+/HER2-low breast cancer as a distinct biological entity

K Sigurjónsdóttir, J Vallon-Christersson + Show 2 more

Open Access

https://doi.org/10.1016/j.esmoop.2023.101274

Copy DOI

Journal: ESMO Open	Publication Date: May 1, 2023
License type: cc-by-nc-nd

Abstract

50P HER2/HER3 heterodimerization can define ER+/HER2-low breast cancer as a distinct biological entity

Full Text

Published version (

Free)

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Paper Title

Journal

Date

Author